Capricor Therapeutics (CAPR) Earnings Date & Reports

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

CAPR is expected to report earnings to fall 171.83% to 42 cents per share on November 17

Capricor Therapeutics CAPR Stock Earnings Reports

Q3'26

Est.

$0.42

Q1'26

Missed

by $0.07

Q4'25

Missed

by $0.11

Q3'25

Est.

$-0.54

Q2'25

Missed

by $0.09

The last earnings report on May 12 showed earnings per share of -58 cents, missing the estimate of -51 cents. With 24.25M shares outstanding, the current market capitalization sits at 243.81M.

View a ticker or compare two or three

CAPR

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days